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Abstract
Background: To investigate the effect of multi-leaf collimators (MLCs) with leaf width of 1.25 mm on the plan
quality of volumetric modulated arc therapy (VMAT) for prostate cancer.
Methods: A total of 20 patients with prostate cancer were retrospectively selected. Using a high definition MLC
(HD MLC), primary and boost VMAT plans with two full arcs were generated for each patient (original plan). After
that, by shifting the isocenter position of the 2nd arc by 1.25 mm in the cranio-caudal direction, we simulated
fluences made with MLCs with leaf width of 1.25 mm. After shifting, primary and boost plans were generated for
each patient (shifted plan). A sum plan was generated by summation of the primary and boost plan for each
patient. Dose-volumetric parameters were calculated and compared.
Results: Both the homogeneity index (HI) and conformity index (CI) of the shifted plans were better than those of
the original plans in primary plans (HI = 0.065 vs. 0.059 with p < 0.001 and CI = 1.056 vs. 1.044 with p = 0.006).
Similarly, the shifted plans for the boost target volume showed better homogeneity and conformity than did the
original plans (HI = 0.060 vs. 0.053 with p < 0.001 and CI = 1.015 vs. 1.009 with p < 0.001). The target mean
dose of the original plans was closer to the prescription dose than that of the shifted plans in the case of
sum plans (81.45 Gy vs. 81.12 Gy with p = 0.001).
Conclusions: Use of extremely narrow MLCs could increase dose homogeneity and conformity of the target
volume for prostate VMAT.
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Background
Volumetric modulated arc therapy (VMAT) has been
widely adopted in the clinic due to its superior ability to
generate optimal dose distributions that deliver prescrip-
tion doses to target volumes while reducing dose to ra-
diosensitive organs [1–3]. Moreover, VMAT is more
efficient in delivery than is intensity modulated radiation
therapy (IMRT), spending fewer monitor units (MUs) as
well as taking less time to deliver a dose distribution to
the patient [4–6]. To acquire the optimal dose distribu-
tion, VMAT modulates photon beam intensities by
varying multi-leaf collimator (MLC) positions, gantry ro-
tation speed and dose rate, simultaneously, while rotat-
ing the gantry around the patient [1, 7–9]. For VMAT,
the resolution of the modulated photon beam intensities,
i.e. the resolution of fluence, is determined by the MLC
leaf width, just as in IMRT [8, 9].
The resolution of the fluence can affect the quality of
a plan, which impacts treatment efficacy as well as com-
plications due to radiotherapy. Therefore, several studies
have investigated the relationship between MLC leaf
width and the quality of IMRT plans [10–12]. They
showed that finer leaf widths can result in more con-
formal dose distributions for target volumes and less
dose delivered to normal tissue when the target volumes
were small and IMRT was used. Rodal et al. demon-
strated that MLCs with fine leaf widths were
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advantageous for biologically adapted radiotherapy,
showing the highest tumor control probability (TCP)
and compartmental equivalent uniform dose (EUD)
when using the finest MLCs among those they tested,
which were MLCs with leaf width of 2.5 mm [11]. Shang
et al. demonstrated the dosimetric advantage of utilizing
narrow MLC leaves in terms of target volume coverage
of prostate IMRT when the treatment was adapted to
consider daily prostate movements for simultaneous ir-
radiation of both prostate and pelvic lymph nodes [12].
For VMAT, few studies have investigated the effect of
MLC leaf width on the plan quality [10, 13]. Hong et al.
have shown the dosimetric advantage of using MLCs
with leaf width of 2.5 mm for VMAT for C-shaped head
and neck (H&N) cancer by performing a phantom study
[10]. Lafond et al. demonstrated that finer MLCs could
reduce dose to organs at risk (OARs) for H&N cancer
by analyzing a total of 16 VMAT plans [13].
Although several studies have reported the effects of
MLC leaf width on the plan quality of VMAT, those
studies were performed with currently available MLCs
such as the high-definition 120™ MLC (HD 120™ MLC,
Varian Medical Systems, Palo Alto, CA), Millennium
120™ MLC (Varian Medical Systems, Palo Alto, CA)
and the Beam Modulator™ (Elekta, Stockholm,
Sweden) [10, 13]. Therefore, those studies were lim-
ited to the leaf width of 2.5 mm, the narrowest leaf
commercially available at present. Consequently, the
effect of MLC leaf widths narrower than 2.5 mm on
VMAT plan quality is unknown. Since it is not clear
whether the use of extremely narrow MLCs with leaf
widths less than 2.5 mm is advantageous for VMAT
plan quality or not, we investigated the impact on plan
quality by simulation of virtual MLCs with leaf width
of 1.25 mm. Since there is currently no commercially
available MLC with 1.25 mm leaf width, we simulated
VMAT plans with those MLCs as described below. We
generated two full arc VMAT plans with the HD 120™
MLC for prostate cancer, with shifting of the isocenter
position of the 2nd arc by 1.25 mm. Although the
width of the MLC leaves were still 2.5 mm for each
arc, due to VMAT plans consisting of each arc
summed together, a 1.25 mm resolution could be simu-
lated through the superposition of two arcs, with a
1.25 mm shift between the arcs. Although this was not a
VMAT plan with real MLCs, we assumed that it was a sin-
gle arc VMAT plan with fluence resolution of 1.25 mm.
After simulating the plans, we compared dose-volumetric
parameters between the original VMAT plans with two
full arcs and no patient shift against the shifted VMAT
plans with two full arcs which were assumed to be a single
arc VMAT plan with 1.25 mm MLC leaf width. By doing
this, we investigated the effect of MLCs with leaf width of
1.25 mm on prostate VMAT plan quality in this study.
Methods
Validation of the fine resolution MLC simulation by CT
image shift method
To examine the validity of the simulated 1.25 mm width
MLCs, created by shifting the isocenter position of the
2nd arc by 1.25 mm using an HD 120™ MLC, we simu-
lated 2.5 mm width MLCs by shifting the isocenter pos-
ition of a solid water phantom by 2.5 mm with 5 mm
width MLCs (Millennium 120™ MLC) in the Eclipse™
system (Varian Medical Systems, Palo Alto, CA). After
that, the dose profile of this simulation was compared to
that of real 2.5 mm width MLCs (HD 120™ MLC).
For the simulation of 2.5 mm width MLCs by using a
CT image shift, one Millennium 120™ MLC in the mid-
dle was fully retracted and other MLCs were fully closed.
A 10 MV photon beam with 100 MU was delivered to a
solid water phantom at a source to surface distance
(SSD) of 100 cm. After that, phantom CT images were
shifted along the cranio-caudal direction by 2.5 mm and
the photon beam with 100 MC was delivered again. A
dose profile was analysed along the cranio-caudal direc-
tion at a depth of 2.5 cm. For acquisition of the profile
with the real 2.5 mm MLCs, the HD 120™ MLC leaf in
the middle was fully retracted and other MLC leaves
were fully closed. A 10 MV photon beam with 200 MU
was delivered to the solid water phantom at 100 cm
SSD. After that, only neighbouring upper and lower
MLCs from the middle MLC were opened, and a photon
beam with 100 MU was delivered. A dose profile was
analysed along the cranio-caudal direction at a depth of
2.5 cm. In addition, a dose profile of the 1.25 mm MLC
simulation with the same method as the 2.5 mm simula-
tion was acquired with the HD 120™ MLC.
Patient selection and simulation
A total of 20 patients with prostate cancer who received
VMAT in our institution were selected retrospectively for
this study. All patients underwent CT scans with a Bril-
liance CT Big Bore™ (Philips, Cleveland, OH) with slice
thickness of 1.5 mm. The resolution of the CT images was
0.98 mm × 0.98 mm (the size of CT voxel = 1.5 × 0.98 ×
0.98 mm3). Patients were immobilized with a Smart Rest™
(Chunsung, Seoul, Republic of Korea), which is a combin-
ation of kneefix and feetfix, in the supine position.
Generation of original VMAT plans
For each patient, two treatment plans were generated, a
plan for a primary target volume (primary plan), and a
plan for a boost target volume (boost plan). The primary
target volume was delineated with a 2 cm margin in
every direction except the posterior and inferior direc-
tions from both the prostate and seminal vesicles. To
the posterior and inferior directions, 1 cm margins were
added in order to reduce dose to the rectal wall. The
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boost target volume was defined with a 0.7 cm margin
in every direction from the prostate. The prescription
doses to primary and boost target volumes were 50.4 Gy
(daily dose = 1.8 Gy) and 30.6 Gy (daily dose = 1.8 Gy),
respectively. Therefore, a total of 81 Gy was delivered to
the prostate only, and a total of 50.4 Gy was delivered to
the seminal vesicles. Both primary and boost plans were
generated with the VMAT technique using the Eclipse™
system. For optimization, the progressive resolution
optimizer 3 (PRO3, ver.10, Varian Medical Systems, Palo
Alto, CA) was used. The dose volume constraints used
during optimization are summarized in Table 1. Initially
these constraints were applied identically for every plan,
and then the dose volume constraints for OARs were
modified by either relaxing or tightening the real-time
updated dose-volume histograms (DVHs) as long as it
did not harm the quality of the target volumes. By doing
this, we accommodated patient-specific differences in
the anatomy of each patient. For dose calculation, the
anisotropic analytic algorithm (AAA, ver.10, Varian
Medical Systems, Palo Alto, CA) was used with a dose
calculation grid of 1 mm. For all VMAT plans, the 10
MV photon beam of TrueBeam STx with HD 120™ MLC
(Varian Medical Systems, Palo Alto, CA) was used. All
VMAT plans were generated with two full arcs. Rectal
wall, bladder and femoral heads were defined as OARs.
The jaw tracking option was not used and the collima-
tors defining cranio-caudal boundaries (Y jaws) were
manually set with a margin of 1 cm from the target vol-
umes. The collimator angle was 0°. The isocenter was
determined such that the target volumes were always
covered by the inner MLCs of the HD 120™ MLC, of
which the leaf width is 2.5 mm. Both primary and boost
plans were normalized to cover 97 % of the target vol-
ume by at least 97 % of the prescription dose. The sum
plans were generated by summation of the primary and
boost plans.
Simulation of VMAT plans using MLCs with 1.25 mm leaf
width (generation of shifted VMAT plans)
To simulate VMAT plans using MLCs with leaf width of
1.25 mm, i.e. half of 2.5 mm, we generated two full arc
VMAT plans, and the isocenter position of the 2nd arc
was shifted in the inferior direction of the patients by
1.25 mm. Although the width of the MLCs were 2.5 mm
for each arc, the resolution of a fluence for a VMAT plan
consisting of the two arcs would be 1.25 mm due to the
superposition of those two arcs. We assumed those
VMAT plans were a single arc VMAT plan with fluence
resolution of 1.25 mm (shifted plan). When shifting the
isocenter position of the 2nd arc by 1.25 mm, we ensured
that the target volumes were fully covered by 2.5 mm
MLCs (inner MLCs of HD 120™ MLC). All conditions
when generating shifted VMAT plans, including dose-
volumetric constraints used during the optimization
process, were identical to those of the original VMAT
plans with the exception of the shift of the isocenter pos-
ition of the 2nd arc. Both primary and boost plans were
generated and normalized to cover 97 % of the target vol-
ume by at least 97 % of the prescription dose, just as in
the original VMAT plans. The sum plans were generated
by summation of the primary and boost plans.
Evaluation of dosimetric changes in the shifted VMAT
plans compared to the original VMAT plans
To evaluate clinical significance of the fluences with
1.25 mm resolution on the VMAT plan quality, we cal-
culated clinically relevant dose-volumetric parameters
for both target volumes and OARs. From each of the
primary and boost plans, the mean dose to the target
volume, dose received by at least 1 % volume of the tar-
get volume (D1%), D99%, D95%, D5%, the percent volume
of the target volume irradiated by at least 95 % of the
prescription dose (V95%), conformity index (CI), homo-
geneity index (HI) and gradient measure (GM) were cal-
culated. The CI was calculated as follows [14].
Table 1 Dose volume constraints for target volumes as well as
organs at risk
Structure Initial dose volume constraints Relative
priority
Primary plan
Primary PTV D100% ≥ 99.5 % of the prescription dose 150
D98% ≥ 100 % of the prescription dose 150
D2% ≤ 101 % of the prescription dose 150
Dmax ≤ 102 % of the prescription dose 150
Rectal wall V44Gy≤ 20 % 100
V30Gy≤ 50 % 100
Bladder V44Gy≤ 20 % 100
V30Gy≤ 50 % 100
Femoral heads V23Gy≤ 50 % 80
Boost plan
Boost PTV D100% ≥ 99.5 % of the prescription dose 150
D98% ≥ 100 % of the prescription dose 150
D2% ≤ 101 % of the prescription dose 150
Dmax ≤ 102 % of the prescription dose 150
Rectal wall V22Gy≤ 20 % 100
V18Gy≤ 50 % 100
Bladder V22Gy≤ 20 % 100
V18Gy≤ 50 % 100
Femoral heads V12Gy≤ 50 % 80
Abbreviations: Dn% Dose received by at least n% volume of the target volume,
VkGy the percent volume of a structure irradiated by at least k Gy, PTV planning
target volume
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Conformity index CIð Þ ¼ Volume of reference isodose
Volume of target volume
ð1Þ
where, the volume of reference isodose = volume irradi-
ated by 97 % of the prescription dose since the
normalization was performed to cover 97 % of the target
volume by at least 97 % of the prescription dose.
The HI was calculated as follows [15].
Homogeneity index HIð Þ ¼ D2%−D98%
D50%
ð2Þ
The GM was calculated as follows [16, 17].
Gradient measure GMð Þ
¼ R50% of prescription dose−Rprescription dose ð3Þ
where, Rx = the sphere radius of which the volume is the
same as the volume of isodose of x, and GM = an indica-
tor showing the degree of normal tissue irradiation by
doses larger than half of the prescription dose.
From the sum plan, the mean dose to the boost target
volume and D1%, D99%, D95% of the boost target volume
were calculated. For the primary target volume, the
mean dose to the primary target volume and D99%, D95%
of the primary target volume were calculated. For OARs,
mean dose, V70Gy, V47Gy and D50% of rectal wall as well
as bladder were calculated. For each femoral head, D50%
and the maximum dose were calculated. To investigate
dose spillage in the normal tissue, V81Gy (100 % of
81Gy), V72.9Gy (90 % of 81Gy), V64.8Gy (80 % of 81Gy),
V50.4Gy (100 % of 50.4 Gy), V45.36Gy (90 % of 50.4 Gy),
V40.32Gy (80 % of 50.4 Gy) and V8.1Gy (10 % of 81 Gy) of
the primary target volume subtracted from the body
structure were calculated. To investigate the statistical
significance of the differences between the original and
shifted VMAT plans, p values were calculated using the
paired t-test, with p values less than 0.05 regarded as sta-
tistically significant in this study.
Results
Validation of the fine resolution MLC simulation by the
shift method
The profiles of the 1.25 mm and 2.5 mm MLC simula-
tions by CT image shift, and the profile of the real
2.5 mm MLCs are plotted in Fig. 1. As shown in Fig. 1,
the profile of the 2.5 mm MLC simulation was almost
the same as the profile of the real 2.5 mm width MLCs
although those profiles were not exactly the same as the
design of the HD 120™ MLC (2.5 mm width) is different
from that of the Millennium 120™ MLC. The full width
at half maximum (FWHM) of the simulation and the
real MLCs of 2.5 mm width were 6.782 mm and
6.970 mm, respectively. Therefore, it seems feasible to
simulate 1.25 mm MLC by shifting the isocenter pos-
ition of the 2nd arc by 1.25 mm with HD 120™ MLC. In
addition, the FWHM of the 1.25 mm MLC simulation
was 4.157 mm.
Differences in dose-volumetric parameters between
original and shifted primary VMAT plans
The clinically relevant dose-volumetric parameters of both
original and shifted VMAT plans for the primary target
volume are shown in Table 2. The average DVH of the pri-
mary target volume is calculated from a total of 20 pa-
tients and plotted in Fig. 2a. The D1% of the primary target
volume of the shifted VMAT plans was lower on average
than that of the original VMAT plans with statistical sig-
nificance (52.0 Gy for original plans vs. 51.7 Gy for shifted
plans with p < 0.001). The average mean dose to the pri-
mary target volume of the shifted VMAT plans was closer
to the prescription dose (50.4 Gy) than that of the original
VMAT plans (50.7 Gy for original plans vs. 50.5 Gy for
shifted plans with p = 0.007). The value of D5% of the
shifted VMAT plans was lower than that of the original
VMAT plans (51.6 Gy for original plans vs. 51.3 Gy for
shifted plans with p = 0.014). Accordingly, the homogen-
eity of the dose distribution inside the primary target vol-
ume of the shifted VMAT plans was better than that of
the original VMAT plans (HI = 0.065 for original plans vs.
0.059 for shifted plans with p < 0.001). In addition, the
conformity of the shifted VMAT plan was better than that
of the original VMAT plans (1.056 for original plans
vs. 1.044 for shifted plans with p = 0.006). However,
the power to spare normal tissue by irradiation of
intermediate dose (50 % of the prescription dose) of
the original VMAT plan was better than that of the
shifted VMAT plans (GM = 1.86 cm for original plans
vs. 2.01 cm for shifted plans with p = 0.041). No statis-
tically significant differences in MU were observed be-
tween the original and the shifted VMAT plans.
Differences in dose-volumetric parameters between
original and shifted boost VMAT plans
The clinically relevant dose-volumetric parameters of
both original and shifted VMAT plans for the boost tar-
get volume are shown in Table 3. The average DVH of
the boost target volume is plotted in Fig. 2b. Similar re-
sults as shown in the primary plans were also observed
in the boost plans. The homogeneity of the dose distri-
bution inside the boost target volume was better in the
shifted VMAT plans than that of the original VMAT
plans (HI = 0.060 for original plans vs. 0.053 for shifted
plans with p < 0.001). Consequently, the value of D1% of
the shifted VMAT plans was lower than that of the ori-
ginal VMAT plans, while the opposite was true for the
D99%, with statistical significance. (D1% = 31.4 Gy for ori-
ginal plans vs. 31.3 Gy for shifted plans with p < 0.001
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and D99% = 29.2 Gy for original plans vs. 29.3 Gy for
shifted plans with p < 0.001). The mean dose of the
shifted VMAT plans (30.6 Gy) was closer to the pre-
scription dose (30.6 Gy) than that of the original VMAT
plans (30.7 Gy) with p value of 0.015. Just as the results
of the primary plans, conformity of the shifted VMAT
plans was better than that of the original VMAT plans
(1.015 for original plans vs. 1.009 for shifted plans with
p < 0.001). However, normal tissue irradiation in the ori-
ginal VMAT plans by intermediate dose was less than
that in the shifted VMAT plans with statistical signifi-
cance. As in the primary plans, no statistically significant
differences in MU were observed between the original
and shifted VMAT plans.
Differences in dose-volumetric parameters between ori-
ginal and shifted sum VMAT plans
The clinically relevant dose-volumetric parameters of
both original and shifted sum VMAT plans are shown in
Table 4. The average DVHs of target volumes of sum
VMAT plans are shown in Fig. 2c and d for both ori-
ginal and shifted VMAT plans. For the boost target vol-
ume, D1% of the shifted VMAT plans was lower than
that of original VMAT plans (83.0 Gy for original plans
vs. 82.6 Gy for shifted plans with p < 0.001) maintaining
same target coverage, which indicates better dose homo-
geneity in the boost target volume of the shifted VMAT
plans than that of the original VMAT plans. The mean
dose of the shifted VMAT plans was closer to the pre-
scription dose (81 Gy) than that of the original VMAT
plans (81.5 Gy for original plans vs. 81.1 Gy for shifted
plans with p = 0.001). The value of D99% was higher in
the shifted VMAT plans than in the original VMAT
plans (78.0 Gy for original plans vs. 78.1 Gy for shifted
plans with p = 0.014). The dose-volumetric parameters
of OARs indicated better plan quality of the shifted
VMAT plans than that of the original VMAT plans,
showing lower values in the shifted VMAT plans, how-
ever, those differences were not statistically significant
(all with p > 0.05). The value of V81Gy of the whole body
showed statistically significant differences between the
Fig. 1 Dose profiles by the simulated and actual multi-leaf collimators (MLCs). Dose profiles of the simulation of 1.25 mm multi-leaf collimator (MLC) with
2.5 mm width MLCs by CT image shift, real 2.5 mm MLCs and the simulation of 2.5 mm MLC with 5 mm width MLCs by CT image shift are plotted with
solid, dashed and dotted lines, respectively. The profile of the simulation of 2.5 mm MLC was almost identical as that of the real 2.5 mm MLCs
Table 2 Average dose-volumetric parameters of primary plans
Original plan Shifted plan p
Primary target volume
D1% (Gy) 51.99 ± 0.36 51.71 ± 0.31 <0.001
Mean dose (Gy) 50.70 ± 0.22 50.50 ± 0.20 0.007
D99% (Gy) 47.87 ± 0.36 47.94 ± 0.32 0.026
D95% (Gy) 49.33 ± 0.08 49.30 ± 0.07 0.107
D5% (Gy) 51.58 ± 0.33 51.32 ± 0.31 0.014
V95% (%) 99.07 ± 0.36 99.15 ± 0.35 0.478
Conformity index 1.06 ± 0.05 1.04 ± 0.04 0.006
Homogeneity index 0.07 ± 0.01 0.06 ± 0.01 <0.001
Normal tissue
Gradient measure (cm) 1.86 ± 0.18 2.01 ± 0.26 0.041
Monitor Unit (MU)
MU 532 ± 115 572 ± 117 0.294
Abbreviations: Dn% Dose received by at least n% volume of the target volume,
Vn% the percent volume of a structure irradiated by at least n% of the
prescription dose
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original and shifted VMAT plans (60.9 cc for original
plans vs. 49.0 cc for shifted plans with p = 0.007).
Discussion
In this study, we investigated the effect of creating finer
resolution fluences on the plan quality of VMAT for
prostate cancer by simulating MLCs with 1.25 mm leaf
width. The results of both primary and boost plans
showed that the dose homogeneity as well as target con-
formity could be improved by using MLCs with leaf
width of 1.25 mm, which was simulated in this study (all
with p < 0.007). When generating a sum plan, piling up
the dose distribution of a boost plan on the homoge-
neous dose distribution inside a primary target volume
can produce high dose conformity to the boost target
volume in a sum plan. Therefore, conformity of the
boost target volume in a sum plan was much improved
by using fine resolution MLCs, while maintaining the
same dose coverage of the target volume (V81Gy of nor-
mal tissue of the original vs. shifted sum plans = 0.12 cc
vs. 0.07 cc with p = 0.083). In sequential radiotherapy of
a patient, improved dose homogeneity and conformity of
the primary and the boost plan induced by the fine reso-
lution MLCs were beneficial for the improving the con-
formity of the boost target volume in a sum plan. The
Fig. 2 Dose-volume histograms (DVHs) of target volumes. Dose-volume histograms (DVHs) of a primary target volume from primary plans (a),
boost target volume from boost plans (b), primary target volume from sum plans (c) and boost target volume from sum plans (d) calculated from
a total of 20 volumetric modulated arc therapy (VMAT) plans for prostate cancer are shown. The average DVHs of original VMAT plans are plotted
with solid black lines while those of the shifted VMAT plans are plotted with dashed black lines. Every single DVHs of original VMAT plans are
plotted with solid gray lines while those of the shifted VMAT plans are plotted with dashed gray lines
Table 3 Average dose-volumetric parameters of boost plans
Original plan Shifted plan p
Boost target volume
D1% (Gy) 31.43 ± 0.24 31.26 ± 0.31 <0.001
Mean dose (Gy) 30.71 ± 0.17 30.57 ± 0.17 0.015
D99% (Gy) 29.18 ± 0.10 29.25 ± 0.09 0.001
D95% (Gy) 29.92 ± 0.05 29.89 ± 0.04 0.095
D5% (Gy) 31.20 ± 0.22 31.02 ± 0.24 0.015
V95% (%) 99.24 ± 0.22 99.38 ± 0.21 0.039
Conformity index 1.02 ± 0.02 1.01 ± 0.02 <0.001
Homogeneity index 0.06 ± 0.01 0.05 ± 0.01 <0.001
Normal tissue
Gradient measure (cm) 1.66 ± 0.26 1.94 ± 0.47 0.027
Monitor Unit (MU)
MU 470 ± 59 495 ± 61 0.219
Abbreviations: Dn% Dose received by at least n% volume of the target volume,
Vn% the percent volume of a structure irradiated by at least n% of the
prescription dose
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results showing improved conformity by using fine reso-
lution MLCs were in agreement with the results of pre-
vious studies on MLC leaf width [10, 13]. The previous
studies also demonstrated that fine resolution MLCs (up
to 2.5 mm leaf width) can reduce dose to OARs. In this
study, the dose-volumetric parameters for OARs indi-
cated slight reduction of dose by using 1.25 mm MLCs,
however, no statistically significant differences between
original and the shifted VMAT plans were observed for
OARs. For each primary and boost plan, the average
values of GM of the shifted plans were higher than those
of the original plans, which indicated more irradiation
by the intermediate dose in the shifted plans. However,
the differences were small: 1.5 mm for the primary plans
and 2.8 mm for the boost plans. Moreover, the normal
tissue volumes irradiated by certain doses (Table 4) of
the shifted plans were always smaller than those of the
original plans except for V8.1Gy. Therefore, no clinically
significant differences were observed in normal tissues
between the original and the shifted plans in this study.
Since the present study was not performed with real
1.25 mm width MLCs but rather performed with the
superposition of 2.5 mm width MLCs by shifting the iso-
center position of the 2nd arc by 1.25 mm, the degree of
freedom of modulation was limited in the present study.
For example, if one MLC retracted and delivered 100
MU at a specific control point, the MUs of two neigh-
bouring beamlets (width of beamlet = 1.25 mm) by this
MLC were both 100 MUs. Therefore, this limitation of
degree of freedom in optimization might cause less im-
provement in dose-volumetric parameters of OARs and
also normal tissues. In addition, the original plans were
generated with two full arcs while the shifted plans were
generated with a single arc with fluence resolution of
1.25 mm (2 full arcs with 2.5 mm resolution vs. 1 full
arc with 1.25 mm resolution). Since previous study has
demonstrated that the plan quality of a VMAT plan with
multiple arcs is better than that with a single arc,
distinguishable improvement in OARs might not be
observed in this study [18]. Although 1 full arc was
used for the shifted plans, the target conformity and
homogeneity were better than those of the original
plans with 2 full arcs.
To simulate VMAT plans with 1.25 mm MLC leaf
width, we shifted the isocenter position of the 2nd arc.
Therefore, we couldn’t evaluate the negative effect of
MLCs with leaf width of 1.25 mm, such as increased
tongue-and-groove effect or greater interleaf leakage
at the leaf junctions. Although this was a limitation of
this study, we were able to identify roughly the advan-
tage of MLCs with narrow leaf width on clinically rele-
vant dose-volumetric parameters in this study. This
data could serve as a basis as well as a motivation for
the development of new MLCs with extremely narrow
leaf width.
The dosimetric advantages for OARs in sum plans
were observed, although the differences between the ori-
ginal and shifted VMAT plans were not statistically sig-
nificant. Moreover, MLCs with 1.25 mm leaf width may
reduce irradiation of normal tissue by high and inter-
mediate doses in sum plans. The decreased doses to the
OARs are meaningful in conjunction with the observed
Table 4 Average dose-volumetric parameters of sum plans
Original plan Shifted plan p
Boost target volume
D1% (Gy) 83.00 ± 0.39 82.55 ± 0.34 <0.001
Mean dose (Gy) 81.45 ± 0.32 81.12 ± 0.28 0.001
D99% (Gy) 77.98 ± 0.44 78.11 ± 0.37 0.014
D95% (Gy) 79.76 ± 0.33 79.68 ± 0.29 0.411
Primary target volume
Mean dose (Gy) 77.33 ± 2.22 77.04 ± 2.25 0.681
D99% (Gy) 55.11 ± 4.17 55.01 ± 4.23 0.267
D95% (Gy) 59.42 ± 6.27 59.16 ± 6.32 0.896
Rectal wall
V70Gy (%) 10.56 ± 3.08 10.38 ± 3.08 0.856
V47Gy (%) 32.40 ± 10.04 31.21 ± 9.51 0.700
D50% (Gy) 32.18 ± 11.35 31.22 ± 11.43 0.791
Mean dose (Gy) 36.68 ± 7.05 36.06 ± 6.97 0.783
Bladder
V70Gy (%) 6.44 ± 4.42 6.37 ± 4.36 0.958
V47Gy (%) 14.35 ± 8.62 14.19 ± 8.51 0.954
D50% (Gy) 12.58 ± 10.11 12.39 ± 10.00 0.952
Mean dose (Gy) 20.62 ± 9.52 20.43 ± 9.46 0.949
Right femoral head
D50% (Gy) 15.09 ± 2.31 14.88 ± 2.39 0.786
Maximum dose (Gy) 27.51 ± 4.10 27.54 ± 4.44 0.981
Left femoral head
D50% (Gy) 15.01 ± 3.55 14.79 ± 3.51 0.846
Maximum dose (Gy) 26.68 ± 3.62 27.34 ± 4.65 0.618
Whole body including target volume
V81Gy (cc) 60.92 ± 14.85 48.96 ± 11.68 0.007
Body – primary target volume
V81Gy (cc) 0.12 ± 0.13 0.07 ± 0.08 0.083
V72.9Gy (cc) 19.23 ± 4.74 18.77 ± 4.59 0.074
V64.8Gy (cc) 43.53 ± 9.61 43.08 ± 9.65 0.290
V50.4Gy (cc) 117.78 ± 23.83 117.06 ± 24.26 0.222
V45.36Gy (cc) 163.60 ± 31.56 163.02 ± 32.28 0.359
V40.32Gy (cc) 226.73 ± 42.88 226.39 ± 44.16 0.707
V8.1Gy (cc) 2963.81 ± 366.10 2979.18 ± 366.93 0.072
Abbreviations: Dn%Dose received by at least n% volume of the target volume,
VnGy the percent volume of a structure irradiated by at least n Gy
Park et al. Radiation Oncology  (2016) 11:85 Page 7 of 9
improved dose homogeneity and conformity of the tar-
get volume. If we increase the number of samples, statis-
tically significant differences might be acquired. This will
be done as a future work.
In theory, MLCs with extremely narrow leaf width can
allow a better match of the beam aperture to the target
projection, and allow high resolution photon beam
optimization with generation of precise field apertures
[10]. Consequently, some clinically relevant dose-
volumetric parameters, such as dose homogeneity in the
target volume, conformity of the prescription dose to
the target volume and slight reductions of doses to
OARs and reduction of normal tissue irradiation by high
dose were improved, while maintaining the same target
coverage as conventional MLCs in this study. The im-
proved dose homogeneity of the target volume was
beneficial, especially for sequential treatment such as
radiotherapy for prostate cancer, since the improved
homogeneity of a primary plan induced improved con-
formity in sum plans. Thus, VMAT plans with extremely
fine resolution MLCs might have an important role in
tackling challenging prostate cases such as prostate pa-
tients with rectal wall very close to the target volume.
Moreover, the reduction of high dose irradiation of nor-
mal tissue as well as the improvement of conformity of
the prescription dose to the target volume by using
MLCs with extremely narrow leaf width could be benefi-
cial in many other treatment situations. For example, re-
ducing the maximum dose delivered to OARs located
nearby the target volume, such as during stereotactic ab-
lative radiotherapy (SABR) of spine cancer. Although in
this study we investigated the dosimetric advantage of
fine resolution MLCs only on VMAT plans for prostate
cancer, other tumor sites which could take advantage of
MLCs with extremely narrow leaf width will be investi-
gated as a future work.
Conclusions
We investigated the effect of MLCs with extremely
narrow leaf widths of 1.25 mm on VMAT plan quality
for prostate cancer. We simulated 1.25 mm MLC leaf
widths by shifting the isocenter position of the 2nd arc
of the VMAT plans using an HD 120™ MLC. The
VMAT plans with the simulated fine resolution MLCs
showed better dose homogeneity inside the target vol-
ume, better target conformity and less dose to normal
tissue nearby the target volume, which was irradiated
by high and intermediate doses, while maintaining the
same target coverage by the prescription dose. It
seems that MLCs with extremely narrow leaf width
are beneficial during sequential radiotherapy due to
the reduction of dose to normal tissue nearby the tar-
get volume.
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